• 2018 Medical Cannabis, all presentations

    Original Date: September 22-23, 2018

    This discounted package includes all of the individual presentations from the conference.

    8.5 CEUs (including 6.5 general and 2.0 pharmacy) approved by OBNM
  • Cannabis and Immunity: Recent HIGH-lights

    Presenter: Heather Zwickey, PhD
    Original Date: September 22, 2018

    The research on cannabis effects on the immune system has been slow coming. However, considering that cannabis receptor 2 is primarily on lymphocytes, there is reason to believe that endocannabinoids and cannabis have profound immune effects. Initially, the only studies of cannabis and immunity were only in people with HIV. Recently, studies of health individuals have been completed.

    This presentation examines the effects of endocannabinoids on immune cells and cytokines. Dr. Zwickey then addresses how cannabis effects the same cells. Finally, she looks at how cannabis can be used in immune dysfunction, such as that found in pain, autoimmunity, and infectious disease.

    1.5 general CEUs approved by OBNM
  • Cannabis for Pain and Opioids Tapering

    Presenter: Michelle Sexton, ND
    Original Date: September 22, 2018

    Human data indicates that cannabis may augment the analgesic effect of opioids (exogenous or endogenous), have “opioid sparing” properties, and work therapeutically in a synergistic and pharmaco-dynamic fashion. Overdose of opiates is the number one cause of death related to prescribed drugs, and there is mounting evidence that chronic administration of opiates may cause “paradoxical pain”. In addition, side effects of opiates are often intolerable for patients. Recent reports indicate that in states where medical/adult use cannabis is available, there has been a drop in opiate prescriptions for Medicaid enrollees.

    This presentation provides an overview of the role of the endocannabinoid system (eCS) in pain, the crosstalk between the endogenous opioid system and the eCS as rationales for using cannabis for pain intervention and tapering of opioid medications. Naturopathic doctors are well-suited to play a role in assisting patients with pain control, opioids tapering and side effects of withdrawal.

    Dr. Sexton reviews cannabinoid and opioid pharmacology (THC, CBD, fentanyl, oxycodone, oxycontin, tramadol), forms of administration, dosing and relative contraindications. She also discusses non-opioid add-on analgesics (Gabapentin, lyrica). A protocol implemented at the UCSD Pain Department, for using a community-based approach, is presented as a means to address opioids prescriptions reduction along with some case studies illustrating the range of responses across patients. Focus is put on community partnership with pain management specialists.

    1.5 pharmacy CEUs approved by OBNM
  • Topical Hemp and Cannabinoids for Beauty and Skin Care

    Presenter: Jeanette Jacknin, MD
    Original Date: September 22, 2018

    Dr. Jacknin starts with a brief overview of what hemp and marijuana is and the differences between them. Next, she discusses the endocannabinoid system and how it is involved in the skin. Following this, the presentations covers the recent scientific studies behind cannabinoids and beauty, anti-aging, acne, itch, atopic eczema, allergic contact dermatitis, wounds psoriasis, and skin cancer.

    1.5 general CEUs approved by OBNM
  • The Evidence Base for Cannabis in Parkinson Disease

    Presenter: Michelle Sexton, ND
    Original Date: September 23, 2018

    The basal ganglia contains an abundance of cannabinoid (CB) receptors. Therefore, it is not surprising that cannabinoids have significant effects on the control of movement, both in health and disease. Cannabinoids interact with three major neurotransmitters of the basal ganglia: dopamine, gamma amino butyric acid (GABA) and glutamate. Cannabis was rarely recommended for treatment of PD in the 20th century primarily because of societal and legal restrictions. However, there are many anecdotal reports on the usefulness of cannabis preparations for treatment of symptoms of PD and for alleviation of the involuntary movements (dyskinesias) that often plague patients who take levodopa for treatment of PD.

    This talk reviews the “evidence base” for cannabis in Parkinson Disease. Most of the evidence for effects is weak with the strongest indications that cannabis and its preparations may be beneficial for improving sleep, quality of life and tremor in patients with PD. Mechanisms associated with some of these effects are reviewed.

    1.5 general CEUs approved by OBNM
  • Oregon Cannabis Law and Naturopathic Doctors

    Presenter: Vincent Sliwoski, JB
    Original Date: September 23, 2018

    This presentation covers the highly dynamic status of state and federal law as it relates to cannabis and naturopathic doctors.

    “Marijuana” is a federally controlled substance, listed on Schedule I of the federal Controlled Substances Act (“CSA”). As of April, 2017, marijuana has been descheduled entirely from the Oregon State Controlled Substances Act (cf. SB 302 and 303). Still, given the status of federal law and Supreme Court jurisprudence on the topic, federal law enforcement authorities retain the right to enforce the federal CSA even in states where cannabis is legal, such as Oregon.

    The federal Drug Enforcement Agency (DEA) issues licenses to physicians to prescribe controlled substances. These licenses do not include the authorization to prescribe Schedule I drugs. Still, courts have held that doctors are protected by the First Amendment free speech rights, which includes the right to discuss (but not prescribe) particular health care options with patients, including cannabis.

    1.0 general CEUs approved by OBNM
  • Medical Cannabis Panel Discussion

    Presenter: Vincent Sliwoski, JB; Michell Sexton, ND; Jeanette Jacknin, MD
    Original Date: September 23, 2018

    0.5 general CEUs approved by OBNM
  • Cannabinoid Therapeutics

    Presenter: Shena Vander Ploeg, ND
    Original Date: September 23, 2018

    With cannabis becoming more mainstream, patients bring lots of questions to clinicians regarding cannabis that many practitioners are left feeling uninformed or unsure of where to start. This presentation offers some perspective to clinicians of how to inform patients of ideas around dosing strategies, methods of consumption, and review of recent research/scientific literature. Dr. Vander Ploeg also covers the development and use of Sativex (outside US) and Epidiolex, which are the pharmaceutical synthetic cannabinoids which have been used internationally in the therapeutic context, and now US has approved Epidiolex.

    Pharmaceutical medications to be discussed: Mention: Epidiolex, Sativex (Outside US)

    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM

Privacy Policy